Loading...
Loading...
LUCD| Name | Value |
|---|---|
| Revenues | 1.2M |
| Cost of Revenue | 1.7M |
| Gross Profit | -0.5M |
| Operating Expense | 11.0M |
| Operating I/L | -11.7M |
| Other Income/Expense | -0.7M |
| Interest Income | 0.1M |
| Pretax | -12.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -12.4M |
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company specializing in gastroesophageal reflux disease (GERD) patients at risk of developing esophageal precancer and cancer. The company's lead products, EsoGuard and EsoCheck, cater to this market by offering an esophageal DNA test and an esophageal cell collection device, respectively. These products enable early detection and monitoring of esophageal adenocarcinoma, a highly lethal form of cancer. Lucid Diagnostics Inc. generates revenue by providing these innovative diagnostic solutions to healthcare providers and patients, contributing to improved patient outcomes and reduced healthcare costs.
